Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash & Equivalents (2016 - 2026)

Lexaria Bioscience's Cash & Equivalents history spans 12 years, with the latest figure at $5.1 million for Q1 2026.

  • Quarterly results put Cash & Equivalents at $5.1 million for Q1 2026, down 20.73% from a year ago — trailing twelve months through Feb 2026 was $5.1 million (down 20.73% YoY), and the annual figure for FY2025 was $1.8 million, down 72.27%.
  • Cash & Equivalents for Q1 2026 was $5.1 million at Lexaria Bioscience, up from $4.3 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $8.5 million in Q2 2024 to a low of $1.4 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $4.7 million (2024), against an average of $5.0 million.
  • The sharpest move saw Cash & Equivalents tumbled 76.74% in 2023, then surged 380.72% in 2024.
  • Year by year, Cash & Equivalents stood at $4.5 million in 2022, then crashed by 56.89% to $2.0 million in 2023, then surged by 313.39% to $8.1 million in 2024, then tumbled by 47.0% to $4.3 million in 2025, then grew by 19.78% to $5.1 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $5.1 million, $4.3 million, and $1.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.